Clinical Trial

Study of the Impact of DPD Activity on the Efficacy of Capecitabine

Study acronym: DPDMAX
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study evaluates the Impact of DihydroPyrimidine Dehydrogenase (DPD) activity on the efficacy of Capecitabine in patients with metastatic breast cancer. The DPD phenotype before the initiation of treatment will be assess and then the patient will be follow up during the treatment with Capecitabine up to 24 month.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2019-12-12; most recent amendment 2026-05-29.
Status change: Recruiting → Active, Not Recruiting 2025-05-20
Status change: Not Yet Recruiting → Recruiting 2020-07-20
Trial Details
NCT Number NCT04198727
Lead Sponsor Centre Antoine Lacassagne
Collaborators: Cerbaliance
Conditions Breast Neoplasm Malignant Female
Enrollment 155 participants
Start Date 2020-07-20
Primary Completion 2026-09 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-02